Johnson & Johnson

Traded on the St. Petersburg Stock Exchange
Johnson & Johnson is an American holding company, leading a group of more than 250 subsidiaries around the world, producing pharmaceuticals, sanitary products. It is the largest manufacturer of medical equipment in the world.
Johnson & Johnson stock price chart
-3%
P/E adj.
Net profit (adj.)
P/B
Book value
Debts
Net debt
Yield
Growth potential

Johnson & Johnson balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Johnson & Johnson cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Johnson & Johnson multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Johnson & Johnson profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Johnson & Johnson assets
Johnson & Johnson cash flows
Johnson & Johnson dividends
2.66%

Johnson & Johnson shares

TickerNameTypeNominal valueISINPrice
JNJ:USJohnson & JohnsonCommon share-US4781601046$164.6

Johnson & Johnson expected events

DateTypeNoteSource
17.02.2023 10:00
Dividends
The last day of purchase for receiving dividends $1.13 per common share for Q1 Fiscal Year 2023.Pictogram of johnsonandjohnson.gcs-web.com  johnsonandjohnson.gcs-web.com
07.03.2023 10:00
Dividends
The company will pay dividends of $1.13 per common share for Q1 Fiscal Year 2023.Pictogram of johnsonandjohnson.gcs-web.com  johnsonandjohnson.gcs-web.com
Johnson & Johnson news
24.01.2023
Johnson & Johnson's GAAP net income for 2022 was $3.52 billion, down 25.7% from $4.736 billion the previous year. Revenue declined 4.4% to $23.706 billion from $24.804 billion a year earlier.
01.11.2022
Johnson & Johnson is buying Abiomed for $16.6 billion, or $380 per share. Company develops and sells medical devices to help or replace pumping function of the failing heart, such as Abiomed and Impella. Abiomed shareholders will also be entitled to another $35.00 per share if certain commercial and clinical milestones are met. Transaction is expected to clo...
20.10.2022
The Johnson & Johnson Board of Directors announced a quarterly dividend of $1.13 per share. The last day to buy securities to receive the dividend is November 18, 2022. The annual dividend yield may reach 2.66%.
18.10.2022
Johnson & Johnson's GAAP net income for 9 months of 2022 was $14.421 billion, down 10.7% from $16.142 billion in the previous year. Revenue increased 3.3% to $71.237 billion from $68.971 billion a year earlier.
General information
Company nameJohnson & Johnson
Tags#pharmacy, #s&p500 index
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK NJ 08933 732-524-2455
Mailing addressONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK NJ 08933
Websitewww.investor.jnj.com
Information disclosurewww.sec.gov